comparemela.com

Latest Breaking News On - Specialty medicines - Page 5 : comparemela.com

GSK split seems to be paying off as vaccines drive upgraded profit guidance

GSK has upgraded its growth outlook for the year ahead after delivering a five per cent increase in sales in 2023.

City ofUnited kingdomChris dorrellEmma walmsleySpecialty medicines

FTSE 100 Live: Stocks fade into the close on fresh US banking nerves

FTSE 100 Live: Stocks fade into the close on fresh US banking nerves
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesNew yorkHelena helmerssonArexvy shingrixRichard hunterMartin beckJim reidRobert gardnerVodafone italiaEmma walmsleyJerome powellRoman zirukElon muskYork community bancorp

FTSE 100 Live: Stocks flat with Nasdaq expected to open lower

FTSE 100 Live: Stocks flat with Nasdaq expected to open lower
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesNew yorkEmma walmsleyVodafone italiaRobert gardnerJerome powellMartin beckJim reidElon muskRichard hunterRoman zirukArexvy shingrixHelena helmerssonIliad group

Market movers: Why CP-T, GIB-A-T, ACB-T and more stocks are seeing action on Wednesday

A survey of North American equities heading in both directions

United kingdomCity ofUnited statesStacy rasgonMark reddEmma walmsleyDave calhounElon muskRuth poratMichael pachterKeith creelJerome dubreuilLaxman narasimhanThomas monteiroJude mccormickSanta clara

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER). The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy. The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 b

Emma walmsleyWikimedia commonsRaises overChief executive officerSpecialty medicinesStock market gameBenzinga proDay trialShingrix vaccine and newly launchedRsv vaccineGsk plcLsk sharesCompound annual growth rateSales growth

vimarsana © 2020. All Rights Reserved.